...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Structure-based discovery of novel 4-(2-fluorophenoxy)quinoline derivatives as c-Met inhibitors using isocyanide-involved multicomponent reactions
【24h】

Structure-based discovery of novel 4-(2-fluorophenoxy)quinoline derivatives as c-Met inhibitors using isocyanide-involved multicomponent reactions

机译:基于结构的新型4-(2-氟苯氧基)喹啉衍生物作为C-Met抑制剂,使用异氰化物涉及的多组分反应

获取原文
获取原文并翻译 | 示例

摘要

The c-Met kinase has emerged as a promising target for the development of small molecule antitumor agents because of its close relationship with the progression of many human cancers, poor clinical outcomes and even drug resistance. In this study, two novel series of 6,7-disubstitued-4-(2-fluorophenoxy)quinoline derivatives containing a-acyloxycarboxamide or a-acylaminoamide scaffolds were designed, synthesized, and evaluated for their in vitro biological activities against c-Met kinase and four cancer cell lines (H460, HT-29, MKN-45, and MDA-MB-231). Most of the target compounds exhibited moderate to significant potency and possessed selectivity for H460 and HT-29 cancer cell lines. The preliminary structure-activity relationships indicated that a-acyloxycarboxamide or a-acylaminoamide as 5-atom linker contributed to the antitumor potency. Among these compounds, compound 10m (c-Met IC50 = 2.43 nM, a multitarget tyrosine kinase inhibitor) exhibited the most potent inhibitory activities against H460, HT-29 and MDA-MB-231 cell lines with IC50 of 0.14 +/- 0.03 mu M, 0.20 +/- 0.02 mu M and 0.42 +/- 0.03 mu M, which were 1.7-, 1.3- and 1.6-fold more active than foretinib, respectively. In addition, concentration-dependent assay and time-dependent assay indicated compound 10m can inhibit the proliferation of H460 cell in a time and concentration dependent manner. Moreover, docking studies revealed the common mode of interaction with the c-Met binding site, suggesting that 10m is a potential candidate for cancer therapy deserving further study. (c) 2020 Elsevier Masson SAS. All rights reserved.
机译:在c-Met激酶已经成为了小分子抗肿瘤药物发展的承诺目标,因为它与许多人类癌症,不良临床后果,甚至耐药性的发展密切相关。在这项研究中,两种新的系列的6,7-二取代-4-(2-氟苯氧基)含喹啉衍生物A-acyloxycarboxamide或-acylaminoamide支架设计,合成,并评价它们的体外生物活性抗c-Met激酶和四个细胞系(H460,HT-29,MKN-45,和MDA-MB-231)。大部分目标化合物表现出中度至显著效力和H460且具选择性和HT-29肿瘤细胞株。初步结构 - 活性关系表明,α-acyloxycarboxamide或-acylaminoamide 5-原子接头促成抗肿瘤效力。在这些化合物中,化合物10M(c-Met的IC 50 = 2.43纳米,多目标酪氨酸激酶抑制剂)与显示出的IC 50为0.14 +/- 0.03亩针对H460,HT-29和MDA-MB-231细胞系的最有效的抑制活性男,0.20 +/- 0.02微米和0.42 +/- 0.03微米,这是1.7-,1.3-和比foretinib 1.6倍的活性,分别。此外,依赖于浓度的测定和时间依赖性的测定表明化合物10米能抑制H460细胞的增殖以时间和浓度依赖的方式。此外,对接研究揭示与c-Met的结合位点相互作用的共模,这表明10米是癌症治疗值得进一步研究的潜在候选。 (c)2020 Elsevier Masson SAS。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号